Nautilus Biotechnology, Inc. (NAUT) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

13/25

Growth 3 Margin 2 Expansion 4 Platform 2 Financial 2

latest quarter score

Earnings Reports

13
Nautilus Biotechnology (NAUT) Q2 2026: Proteoform R&D Headcount Triples as Broad Scale Timeline Slips
July 28, 2026
11
Nautilus Biotechnology (NAUT) Q1 2026: Operating Expenses Fall 14% as Commercial Launch Readiness Advances
June 16, 2026
10
Nautilus Biotechnology (NAUT) Q2 2025: Operating Expenses Down 18% as Platform Validation Accelerates
June 16, 2026
10
Nautilus (NAUT) Q3 2025: OpEx Down 19% as Platform Readies for Early Access Expansion
June 16, 2026
11
Nautilus Biotechnology (NAUT) Q4 2025: Operating Expenses Down 23% as Platform Nears Commercialization
June 15, 2026
11
Nautilus (NAUT) Q1 2025: Operating Expenses Down 13% as Platform Readiness Accelerates
July 07, 2025

Browse all companies